Drug Profile
Research programme: multi-targeted cancer therapeutics - Curis
Alternative Names: CU-0201; CU-201; CU-903; CU-906Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Curis
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Cyclin-dependent kinase inhibitors; Histone deacetylase inhibitors; Mitogen-activated protein kinase inhibitors; MTOR protein inhibitors; Src-Family kinase inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 18 Oct 2012 Curis files an IND application with the US FDA for refractory lymphomas and multiple myeloma
- 04 Apr 2012 Pharmacodynamics data from preclinical studies in Cancer presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)